Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells
暂无分享,去创建一个
T. Luetkens | D. Atanackovic | A. Rapoport | R. Koka | Etse H. Gebru | S. Dahiya | N. Hardy | K. Hankey | Haroon Ahmad | P. Lesho | D. Omili | T. Iraguha | Kenneth A. Dietze | Yamini K. Kathari | Nishanthini Dishanthan | J. Yared | Haroon Ahmad | Michael E. Kallen | Jean Clement | Lily Pham | Mazhar Khalid | Xiaoxuan Fan | Esther Park | Jillian M. Baker | Ashraf Badros | Hakan Kocoglu | Michael E Kallen | Ashraf Z. Badros
[1] S. McColl,et al. Chemokine-Driven Migration of Pro-Inflammatory CD4+ T Cells in CNS Autoimmune Disease , 2022, Frontiers in Immunology.
[2] H. Einsele,et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies , 2022, Blood Cancer Journal.
[3] A. Laganà,et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy , 2021, Nature Medicine.
[4] S. Jagannath,et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study , 2021, The Lancet.
[5] H. Goldschmidt,et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. , 2021, The New England journal of medicine.
[6] C. Venugopal,et al. Strategies to Enhance the Efficacy of T-Cell Therapy for Central Nervous System Tumors , 2020, Frontiers in Immunology.
[7] Jianfeng Zhou,et al. CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain , 2020, Frontiers in Oncology.
[8] M. Awais,et al. IP-10 Promotes Blood–Brain Barrier Damage by Inducing Tumor Necrosis Factor Alpha Production in Japanese Encephalitis , 2018, Front. Immunol..
[9] Hans Bitter,et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia , 2018, Nature Medicine.
[10] David W. Holman,et al. Chemokines in the balance: maintenance of homeostasis and protection at CNS barriers , 2014, Front. Cell. Neurosci..
[11] M. Raffeld,et al. B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma , 2013, Clinical Cancer Research.
[12] E. Bettelli,et al. Cutting Edge: Loss of α4 Integrin Expression Differentially Affects the Homing of Th1 and Th17 Cells , 2011, The Journal of Immunology.
[13] S. McColl,et al. Inhibition of CCR6 Function Reduces the Severity of Experimental Autoimmune Encephalomyelitis via Effects on the Priming Phase of the Immune Response1 , 2009, The Journal of Immunology.
[14] T. Gingeras,et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells , 2006, The Journal of experimental medicine.
[15] D. Mahad,et al. Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis , 2002, Journal of neurology, neurosurgery, and psychiatry.
[16] Simon A. Jones,et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes , 1996, The Journal of experimental medicine.